SCHEMBL31472517

SCHEMBL31472517

CC(C)CN1CCC(C(=O)Nc2nccc(-c3c[nH]c4cnccc34)n2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1B Q9Y463 7/20 0.48
▸ CDK2 P24941 6/20 0.48
▸ IGF1R P08069 4/20 0.48
▸ DYRK1A Q13627 12/20 0.47
▸ GSK3B P49841 10/20 0.47
▸ WNT1 P04628 7/20 0.47
▸ TTK P33981 1/20 0.46
▸ NFATC1 O95644 1/20 0.45
▸ JUN P05412 1/20 0.44
▸ MAPK8 P45983 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ DYRK3 O43781 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ CLK3 P49761 1/20 0.42
▸ CDK5 Q00535 1/20 0.42
▸ CDK5R1 Q15078 1/20 0.42
▸ DYRK2 Q92630 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ DYRK4 Q9NR20 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25644903 1.00 DYRK1B (0.48) DYRK1BCDK2IGF1RDYRK1AGSK3B
SCHEMBL25420762 0.84 DYRK1A (0.53) DYRK1BDYRK1AGSK3BWNT1NFATC1
SCHEMBL31472499 0.82 GSK3B (0.45) DYRK1BDYRK1AGSK3BWNT1NFATC1
SCHEMBL25644934 0.82 GSK3B (0.45) DYRK1BDYRK1AGSK3BWNT1NFATC1
SCHEMBL25643414 0.77 CDK2 (0.35) DYRK1BCDK2IGF1RDYRK1AGSK3B
SCHEMBL25421363 0.70 DYRK1A (0.48) DYRK1BCDK2IGF1RDYRK1AGSK3B
SCHEMBL30461704 0.70 DYRK1A (0.48) DYRK1BCDK2IGF1RDYRK1AGSK3B
SCHEMBL25421944 0.68 DYRK1A (0.58) DYRK1BDYRK1AGSK3BWNT1NFATC1
SCHEMBL30461690 0.68 DYRK1A (0.58) DYRK1BDYRK1AGSK3BWNT1NFATC1
SCHEMBL20946483 0.68 GSK3B (0.77) DYRK1BDYRK1AGSK3BWNT1DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS DYRK2, DYRK1A, DYRK1B DYRK1B 3/4885CDK2 549/4885IGF1R 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback